|
Post by golfeveryday on Jun 10, 2018 18:59:41 GMT -5
When I have conversations off this board Dexcom comes up over and over again. We have reps that used to work at Dexcom that are looking forward to the turn around here like they had there. Dexcom reps are getting asked questions about Afrezza by the Endo’s. They are very friendly towards us. And people higher up are “expecting great things” from us:-) All Good! I think it would be a wise move for Kevin Sayer to make a move now while his pps is way up and put two old Minimed pieces back together; the CGM; and afrezza. what would you see that looking like? Would mnkd partner with one cgm in Dexcom and not Abbott Libre?
|
|
|
Post by joeypotsandpans on Jun 10, 2018 19:12:58 GMT -5
Always nice to get someone that has been on the other side....held some key positions with NVO and will be able to exploit the weaknesses of the barbaric side of NVO, so now we have two from the each of the barbaric, obsolete (my word) and unpredictable Raa's to lead the way with networks galore. From her time at NVO: Novo Nordisk Pharmaceuticals Senior Director, Managed Markets Strategy & Health Economic Outcomes Novo Nordisk Pharmaceuticals January 2006 – January 2012 (6 years 1 month) Novo Nordisk A/S Executive Director Health Economics & Outcomes Research Novo Nordisk A/S January 2006 – January 2012 (6 years 1 month) Novo Nordisk AVP, Managed Markets Strategy & Operations Novo Nordisk 2006 – January 2012 (6 years) Read more: mnkd.proboards.com/thread/10088/castagna-welcome-garrett-mannkind-family?page=1#ixzz5I2v7Sz7q Joey, "the other side"? The other side of the Raa insulin spectrum, like getting a free agent from the rival team....they know where their former team's strengths and weaknesses lie.....more importantly they also have the connections with the same key people at the insurance levels that the other companies leveraged with "health economic outcomes" (as stated per her resume). To have one individual the capacity of Dr. Kendall from LLY and ADA and another in the marketing arena from NVO and also having been with BMY and SNY along with some time at Dexcom are vastly different than having previous management learning via trial and error as they went. This is furthering the transformation of MNKD evolving into a highly respectable pharmaceutical entity. So all other competing companies become "the other side" from which we can attract key talent that see the young up and coming future champion. It reminds me of when the Miami Heat brought in Lebron and Chris Bosh to join Wade and win back to back championships in 2012 and '13. Players of that caliber don't go to the "other sides" unless they're pretty confident they can get the "trophy" or "ring", again this company is putting together its own team of all stars
|
|
|
Post by sayhey24 on Jun 10, 2018 19:17:09 GMT -5
GED - Dexcom buys MNKD for shares.
Dexcom is already partnered with Onduo. CGMs will become a commodity market but afrezza won't. Dexcom then makes a decision - do they put their own Onduo in place or do they expand in the Technosphere drug market or both. I would think One Drop may want to play in this game.
The thing about Dexcom sales reps is they are already going where the MNKD reps need to go.
Onduo has an issue. They have a big boat anchor around its neck called Sanofi. What they have proven to date is they don't move fast. Their version of business value at start up speed is business value at bloated corporate speed.
|
|
|
Post by golfeveryday on Jun 10, 2018 19:26:48 GMT -5
GED - Dexcom buys MNKD for shares. Dexcom is already partnered with Onduo. CGMs will become a commodity market but afrezza won't. Dexcom then makes a decision - do they put their own Onduo in place or do they expand in the Technosphere drug market or both. I would think One Drop may want to play in this game. The thing about Dexcom sales reps is they are already going where the MNKD reps need to go. Onduo has an issue. They have a big boat anchor around its neck called Sanofi. What they have proven to date is they don't move fast. Their version of business value at start up speed is business value at bloated corporate speed. would be a strong move on their part for sure. I could see them make a move for Afrezza but not the whole company. I could actually see a buy in as opposed to buyout.
|
|
|
Post by sayhey24 on Jun 10, 2018 19:36:24 GMT -5
GED - ADA2018 should be a pretty exciting place for MNKD this year. Everyone and their brother is going to come with Cloud monitoring services. Dexcom, Abbott and a few others are coming with CGMs. Maybe San Meditech will show up again with their new CGM en.sanmeditech.com/index.php/products/detail/id/1I would do several live afrezza demonstrations each day on the exhibit floor using both the Libre and G6. While everyone else will have monitoring tools, afrezza is the only solution to the root problem - meal time spikes.
|
|
|
Post by falconquest on Jun 10, 2018 20:10:09 GMT -5
So how does this differ from Chief Commercial Officer? McCauley deals with regulatory affairs related to commercialization of products and marketing is well, marketing?
|
|
|
Post by od on Jun 10, 2018 20:13:28 GMT -5
The other side of the Raa insulin spectrum, like getting a free agent from the rival team....they know where their former team's strengths and weaknesses lie.....more importantly they also have the connections with the same key people at the insurance levels that the other companies leveraged with "health economic outcomes" (as stated per her resume). To have one individual the capacity of Dr. Kendall from LLY and ADA and another in the marketing arena from NVO and also having been with BMY and SNY along with some time at Dexcom are vastly different than having previous management learning via trial and error as they went. This is furthering the transformation of MNKD evolving into a highly respectable pharmaceutical entity. So all other competing companies become "the other side" from which we can attract key talent that see the young up and coming future champion. It reminds me of when the Miami Heat brought in Lebron and Chris Bosh to join Wade and win back to back championships in 2012 and '13. Players of that caliber don't go to the "other sides" unless they're pretty confident they can get the "trophy" or "ring", again this company is putting together its own team of all stars Well said Joey. I was concerned that successful, mainstream Pharma/Bio organizations were being labeled 'the dark side'. (A retired mainstream executive, I bristle when the industry in demonized.) Advanced discovery + exquisite launch preparation/execution (read, clearly communicated compelling science/safety/efficacy) + focused marketing = success. It is good to have another shot at two and three.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 10, 2018 21:11:56 GMT -5
June 2018 – Present (1 month)Westlake Village, California Seems we can afford her and we’re about to do some marketing and she has experience with Dexcom. I'm not digging this NEW HIRE. What kind of a BLIP is 7 Months at DEXCOM? From 30K foot level she seems like a difficult employee who cant stay in one spot too long. That tells me she's all FLUFF and not SUBSTANCE. I hope I'm wrong.
|
|
|
Post by golfeveryday on Jun 10, 2018 21:14:18 GMT -5
June 2018 – Present (1 month)Westlake Village, California Seems we can afford her and we’re about to do some marketing and she has experience with Dexcom. I'm not digging this NEW HIRE. What kind of a BLIP is 7 Months at DEXCOM? From 30K foot level she seems like a difficult employee who cant stay in one spot too long. That tells me she's all FLUFF and not SUBSTANCE. I hope I'm wrong. hopefully she won’t have to stay long. 😜
|
|
|
Post by brotherm1 on Jun 10, 2018 21:29:59 GMT -5
June 2018 – Present (1 month)Westlake Village, California Seems we can afford her and we’re about to do some marketing and she has experience with Dexcom. I'm not digging this NEW HIRE. What kind of a BLIP is 7 Months at DEXCOM? From 30K foot level she seems like a difficult employee who cant stay in one spot too long. That tells me she's all FLUFF and not SUBSTANCE. I hope I'm wrong. Perhaps she was bored trying to market machines. Afrezza is the antithesis of boring. Think about it, how creative and outstanding can you get marketing a machine?
|
|
|
Post by theshiv on Jun 10, 2018 21:49:22 GMT -5
How about we give this woman a chance. If Mike is fine with her, I'm good with it.
|
|
|
Post by bones1026 on Jun 10, 2018 22:20:00 GMT -5
How about we give this woman a chance. If Mike is fine with her, I'm good with it. And we say it all the time, if money situation is so dire..and we only have a few months of cash left, you don’t hire executives at this point..nor do highly respected execs leave large BP to come to a dying company...
|
|
scho
Newbie
Posts: 5
Sentiment: Long
|
Post by scho on Jun 10, 2018 22:35:16 GMT -5
Absolutely
|
|
|
Post by awesomo on Jun 10, 2018 23:31:12 GMT -5
June 2018 – Present (1 month)Westlake Village, California Seems we can afford her and we’re about to do some marketing and she has experience with Dexcom. I'm not digging this NEW HIRE. What kind of a BLIP is 7 Months at DEXCOM? From 30K foot level she seems like a difficult employee who cant stay in one spot too long. That tells me she's all FLUFF and not SUBSTANCE. I hope I'm wrong. Sometimes positions aren't the right fit for one or both parties, sometimes a better opportunity presents itself. Judging her based on this without knowing the details is ridiculous.
|
|
|
Post by babaoriley on Jun 11, 2018 1:37:18 GMT -5
How about we give this woman a chance. If Mike is fine with her, I'm good with it. You need to stop posting reasonable stuff - immediately!
|
|